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Abstract 
Aim: To retrospectively evaluate the use of proton pump inhibitor infusions. 
Methods: A retrospective chart review was conducted of all patients who received an 80 mg bolus of 
esomeprazole follow by an infusion at 8 mg/hr. An analysis was performed to determine if a Blatchford 
Score of > 5 was a predictor of upper gastrointestinal ulcers. 
Results: 300 patients received high dose esomeprazole over a 15 month period. 32% had an ulcer 
identified on endoscopy. Gastritis and esophagitis were the second most common diagnosis accounting 
for 16% of patients. A Blatchford Score of >5 as a predictor of upper gastrointestinal ulcers had a 
sensitivity of 86.5% with a specificity of 32%. 
Conclusion: Utilizing the Blatchford Score to predict patients that have an upper gastrointestinal ulcer 
does not appear to be effective in clinical practice. 
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Introduction
The role of proton pump inhibitors (PPIs) for the prevention of 
rebleeding in patients after therapeutic endoscopy for non-variceal 
upper gastrointestinal tract bleeding (UGIB) is well established. 
Acidic environments prevent platelet aggregation and coagulation 
as well as cause clot lysis;1,2 therefore, raising the pH of gastric 
contents creates an environment suitable for both clot formation 
and stabilization. A sustained pH of 6 prevents clot lysis and allows 
for platelets to aggregate. Both proton pump inhibitors (PPIs) and 
histamine 2 receptor antagonists raise gastric pH, however, only PPIs 
have the desired potency to achieve a sustained pH of 6.3,4
Initial studies evaluating PPIs for suspected UGIB failed to 
illustrate clinical benefits.5 In these studies, endoscopy was not utilized 
as a treatment modality; rather, it was used solely as a diagnostic tool. 
Haemostasis with endoscopy is the treatment of choice for non-variceal 
UGIB as it has shown to reduce bleeding and the need for surgery, as 
well as decrease mortality.6,7 Later study initiating high dose PPIs as 
a bolus and 72 hour infusion post-therapeutic endoscopy showed a 
decrease in re-bleeding.8 Further studies showed that initiating a PPI 
bolus and infusion prior to endoscopy resulted in decreasing oozing at 
the site of the ulcer and a reduction in the need for endoscopic therapy 
without affecting other clinical outcomes.9,10 The authors suggested 
that high risk patients with suspected non-variceal UGIB may benefit 
from high dose PPIs prior to endoscopy.
High risk patients with UGIB who may benefit from PPIs prior 
to endoscopy is challenging. The Blatchford Score was created to 
identify high risk patients who may require intervention.11,12 Although 
a Blatchford Score of greater than zero has shown to good sensitivity 
for determining high risk patients, it lacks the specificity to make it 
useful in clinical practice.13,14 The objective of this study was determine 
if patients are appropriately receiving PPIs for suspected UGIB in 
the emergency department (ED) and to evaluate the sensitivity and 
specificity of a Blatchford Score of >5 as a predictor of patient with 
UGIB ulcers.
Methods
This was a retrospective review of patients who received a PPI 
bolus and infusion while in the ED at a busy community hospital 
who receives >95,000 visits annually. Patients were identified 
through a pharmacy medication records database. Information was 
retrospectively collected over a 15 month period. To be included in 
the study, patients must have received an 80mg bolus of esomeprazole 
and been initiated on an esomeprazole drip at 8mg/hr while in the 
ED. Esomeprazole was chosen as this was the formulary PPI agent 
during the time of study. Patients were excluded from the study if care 
was withdrawn or had advanced directives that precluded them from 
receiving invasive procedures or dictated conservative care measures. 
This study was approved by the institutional review board.
To be classified as appropriate, patients had to have an upper 
gastrointestinal ulcer identified upon endoscopy during their inpatient 
stay or in the ED. When an endoscopy did not identify an ulcer or 
when a patient did not undergo endoscopy, they were classified as 
inappropriate. Subsequently, these patients were categorized into 
several categories based on the endoscopic findings or as not having 
an endoscopy: variceal upper GI bleed, gastritis or esophagitis, 
endoscopy not done, normal upper gastrointestinal tract, or other (i.e: 
hiatal hernia, atriovenous malformation).
For each patient, all scoring components of the Blatchford Score 
were collected (Table 1). At the conclusion of data collection, a 
Blatchford Score was calculated for each patient. A 2x2 table was 
constructed to determine the sensitivity and specificity of a Blatchford 
Score of >5 as a predictor of the presence of an upper GI ulcer. The 
definitive diagnosis of an ulcer was made through retrospective 
review of patient’s charts and upper GI endoscopy reports. Patients 
that did not undergo upper GI endoscopy were considered not to have 
an ulcer present.
 The primary objective of this study was to determine the number 
of patients that received an esomeprazole bolus of 80 mg followed 
by an infusion at 8mg/hr and had an upper GI ulcer identified upon 
endoscopy. A secondary objective of this study was to determine the 
sensitivity and specificity of a Blatchford Score of >5 for identifying 
patients with an upper GI ulcer.
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Abstract
Aim: To retrospectively evaluate the use of proton pump inhibitor infusions.
Methods: A retrospective chart review was conducted of all patients who received 
an 80 mg bolus of esomeprazole follow by an infusion at 8 mg/hr. An analysis 
was performed to determine if a Blatchford Score of > 5 was a predictor of upper 
gastrointestinal ulcers.
Results: 300 patients received high dose esomeprazole over a 15 month period. 32% 
had an ulcer identified on endoscopy. Gastritis and esophagitis were the second most 
common diagnosis accounting for 16% of patients. A Blatchford Score of >5 as a 
predictor of upper gastrointestinal ulcers had a sensitivity of 86.5% with a specificity 
of 32%.
Conclusion: Utilizing the Blatchford Score to predict patients that have an upper 
gastrointestinal ulcer does not appear to be effective in clinical practice.
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Table 1 Blatchford Score were collected
Risk marker Score component value
Blood urea nitrogen (mg/dL)
>18.2to <22.4 2
>22.4 to<28 3
>28 to< 70 4
>70 6
Hemoglobin men (g/dL)
>12 to <13 1
>10 to <12 3
<10 6
Hemoglobin women (g/dL)
>10to<12 1
<10 6
Systolic blood pressure (mmHg)
>100to<109 1
>90to99 2
<90 3
Other markers
Pulse Rate >100 Beats/Min 1
Presentation with Melena 1
Presentation with Syncope 2
Hepatic Disease 2
Heart Failure 2
Results
Over a 15 month period 313 patients were initiated on an 80mg 
bolus of esomeprazole followed by an infusion at 8mg/hr. Of these 
patients, 13 were excluded due to withdrawal of care or an advance 
directive prohibited them from undergoing upper GI endoscopy. The 
median time to endoscopy was 19.5 hours and ranged from 1 to 433.5 
hours. In the remaining 300 patients an ulcer was found during an 
upper GI endoscopy in 96 (32%) patients (Figure 1). Among the 
patients that an ulcer identified, 31 (10.3%) required intervention such 
as cauterization and/or epinephrine injections to stop bleeding. The 
most common finding upper GI pathology found in patients that did 
not have an ulcer was gastritis or esophagitis, followed by variceal 
UGIB at (16%) and (12%) respectively. Sixteen percent of patients 
did not undergo an upper GI endoscopy while present in the ED or 
during their inpatient stay.
 The median Blatchford Score calculated was 8 and ranged from 0 
to 20 (Figure 2). A Blatchford Score of >5 correctly predicted an ulcer 
in 84 patients (Table 2). The sensitivity of a Blatchford Score >5 for 
predicting an ulcer in patients the received an esomeprazole bolus and 
infusion while in the ED was 86.5% with a specificity of 32%.
Table 2 A Blatchford Score of >5 correctly predicted an ulcer in 84 patients
Endoscopic findings
Ulcer No ulcer
Blatchford >5 84 (TP*) 138 (FP*)
Score <5 13 (FN*) 65 (TN*)
Total 97 203
*True Positive (TP); False Positive (FP); False Negative (FN); True Negative 
(TN)
Figure 1 300 patients an ulcer was found during an upper GI endoscopy in 
96 (32%) patients.
Figure 2 The median Blatchford Score calculated was 8 and ranged from 0 
to 20
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Discussion
A PPI bolus and infusion after therapeutic endoscopy reduces the 
rate of re-bleeding among patients with upper GI ulcers. In high risk 
patients, a bolus and infusion prior to endoscopy reduces the need for 
endoscopic intervention and the signs of bleeding. Determining which 
patients are at high risk is difficult. Only 32% of patients over a 15 
month period received an esomeprazole bolus and infusion while in 
the ED had an ulcer. Almost 30% of patients did not have any upper 
GI pathology present or did not undergo endoscopy.
The administration of PPIs is not without risk. Chronic acid 
suppression has been associated with life threatening electrolyte 
abnormalities.15 Critically ill patients receiving acid suppression 
for stress ulcer prophylaxis are at increased risk for respiratory 
infections.16–18 Additionally, the use of PPIs has been associated 
with the development of Clostridium difficile infections.19–21 Recent 
studies have suggested that there is a dose response relationship with 
administration of PPIs and that risk of Clostridium difficile infection 
can develop in as soon as three days with PPI therapy.22,23 Inappropriate 
administration of high dose PPIs in the ED could place patients at 
an increased risk for the future development for Clostridium difficile 
infections later in their hospital course.
Variceal upper GI bleeding was the second most common 
diagnosis among patients reviewed. Potential treatment options 
for patients with variceal bleeding include the use of somatostatin 
analogues and band ligation.23 High dose PPIs in combination with 
octreotide, a somatostatin analogue, in patients with variceal bleeding 
has not shown benefit in regards to patient outcomes or transfusion 
requirements.24 Providers often initiate PPI bolus and infusions 
empirically in patients with presumed variceal bleeding despite the 
lack of proven benefit. Of the patients in our study that were found 
to have variceal bleeding, none had concomitant upper GI ulcers and 
were therefore unlikely to have received additional benefit from the 
use of high dose esomeprazole. In the future, exclusion of patients 
with variceal bleeding may reduce the unnecessary use of high dose 
PPIs.
This study identified that more objective criteria is needed to 
identify patients at high risk for upper GI ulcers. The Blatchford Score 
was developed to identify patients that required treatment to manage 
their bleeding12,13 While this scoring system has been identified 
by some practice guidelines as a tool for identifying patients that 
may require intervention,25 its usefulness in clinical practice may 
be limited.13,26,27 In our study we attempted to evaluate whether a 
Blatchford Score of >5 would predict patients that would have an 
ulcer identified upon endoscopy. Previous studies have shown that 
scores of 5 or greater may an appropriate threshold for which patients 
may require intervention.12,26 In our study, a sensitivity analysis 
revealed that the Blatchford Score of >5 would identify most patients 
with upper GI ulcers but had a specificity of only 32% which limits its 
application in clinical practice.
Several limitations exist in this study. Patients were included 
in this study were initiated on an esomeprazole bolus and infusion 
while in the ED regardless of whether they were continued on the 
infusion if they were admitted to the hospital. Therefore the duration 
of the infusion was not taken into account when evaluating their 
use, although this was unlikely to have influenced the incidence of 
identifiable ulcers. In addition our study included all patients in the 
ED that had received a bolus and infusion of esomeprazole over a 
15 month period which represented a relatively non-specific patient 
population. More stringent exclusion criteria may provide better 
results in future studies evaluating the utility of the Blatchford Score. 
As the patients in our study were initiated on therapy in the ED, results 
may differ for inpatients initiated on high dose PPIs.
Conclusion 
The findings of our study illustrated that only 32% of patients in 
the ED initiated on high dose esomeprazole had an ulcer identified 
on endoscopy. A Blatchford Score of >5 may not be helpful in 
determining high risk patients who may benefit from a PPI bolus 
and infusion prior to endoscopy. Future study is needed to identify 
objective criteria that can help detect patients that could benefit from 
PPIs prior to endoscopy.
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